What is the current market size?

The Prostate Specific Antigen (PSA) Blood Based Biomarker market size reached USD 1.2 billion in 2023, driven by increasing adoption in prostate cancer diagnostics and advancements in blood-based testing technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, fueled by rising geriatric populations and growing awareness of early cancer detection through PSA blood tests.

What are the key drivers of market growth?

Key drivers include rising prostate cancer incidence, advancements in liquid biopsy techniques, and increasing healthcare expenditure in developed economies.

What challenges does the market face?

Challenges include test specificity limitations, regulatory hurdles, and reimbursement constraints, which may slow adoption in emerging markets.

Which regions are leading the market?

North America leads due to advanced healthcare infrastructure, followed by Europe, while Asia-Pacific shows high growth potential from expanding diagnostic access.

Who are the leading companies in the market?

Leading companies include Qiagen, Beckman Coulter, Roche Diagnostics, and Abbott, focusing on innovation and global distribution networks.

What future opportunities exist?

Future opportunities lie in personalized medicine, AI-driven diagnostics, and expanding access to PSA testing in underdeveloped regions.

How is technology advancing this market?

Advances in multiplex testing and AI-based data analysis are enhancing PSA biomarker accuracy and efficiency in prostate cancer screening.

What is the regulatory environment like?

The market operates under strict FDA and EMA guidelines, with ongoing efforts to standardize PSA testing protocols globally for improved patient outcomes.

Prostate Specific Antigen (PSA) Blood Based Biomarker Growth Analysis & Future Outlook 2033

Prostate Specific Antigen (PSA) Blood Based Biomarker by Application (Diagnostics, Drug Discovery, Personalized Medicine, Others), by Types (Screening Biomarker, Diagnosis Biomarker), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size | CAGR 6.8 Forecast 2033

Prostate Specific Antigen (PSA) Blood Based Biomarker Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Prostate Specific Antigen (PSA) Blood Based Biomarker Market Overview

The Prostate Specific Antigen (PSA) Blood Based Biomarker market represents a critical segment in oncology diagnostics, leveraging blood-based assays to detect prostate cancer and monitor treatment efficacy. This market is pivotal in addressing the rising global burden of prostate cancer, driven by aging populations and increased screening adoption. The PSA Blood Based Biomarker market size is projected to reach USD 1.8 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033, reflecting robust industry expansion and evolving diagnostic precision. Technological innovations, such as next-generation sequencing and AI-driven analytics, are reshaping the growth outlook, while regulatory reforms and reimbursement policies further catalyze market adoption.

Loading chart…

Key forces shaping the Prostate Specific Antigen (PSA) Blood Based Biomarker market include the integration of liquid biopsy technologies and AI-powered biomarker analytics, which enhance diagnostic accuracy. Regulatory frameworks, such as FDA approvals for advanced PSA tests, are accelerating market standardization. North America dominates the market due to high healthcare expenditure and early-stage adoption of cutting-edge diagnostics, while the Asia-Pacific region emerges as the fastest-growing, fueled by rising awareness and healthcare digitization. Strategic collaborations among diagnostic firms and pharmaceutical companies are intensifying competitive dynamics, ensuring the sector remains at the forefront of personalized cancer care.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	761.70 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ProteoMediX; Cleveland Diagnostics; Randox; Roche; GENFIT; Nutech Cancer Biomarkers; OGT (Sysmex Group); Minomic; Creative Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Prostate Specific Antigen (PSA) Blood Based Biomarker market is poised for robust expansion due to rising global prostate cancer incidence, particularly in aging populations. Early detection demand and improved survival rates directly correlate with increased adoption of PSA testing, driving market size growth.

Advancements in multiparametric PSA biomarker technologies, such as Prostate Specific Antigen (PSA) Blood Based Biomarker market-specific liquid biopsies and AI-driven diagnostic analytics, are enhancing test accuracy and reducing false positives. These innovations accelerate adoption in clinical settings and bolster the growth forecast for next-generation solutions.

Restraints2 items

Regulatory scrutiny and delayed approvals for novel PSA biomarkers, particularly in the EU and U.S., hinder market entry for emerging players. Stringent validation requirements increase R&D costs and slow time-to-market.

High costs associated with advanced PSA testing—such as Prostate Specific Antigen (PSA) Blood Based Biomarker market-specific genomic panels—limit accessibility in low- and middle-income countries, restricting broader adoption despite rising prevalence.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped growth potential as healthcare infrastructure expands. Rising awareness of proactive prostate cancer screening and investment in diagnostic labs could drive Prostate Specific Antigen (PSA) Blood Based Biomarker market size expansion by 2030.

Strategic collaborations between biotech firms and digital health platforms enable AI-integrated PSA diagnostics. These partnerships open new revenue streams and position players to capitalize on the growth forecast for precision oncology solutions.

Challenges2 items

Competition from alternative diagnostics, such as urine-based PCA3 tests and imaging-based prostate cancer detection, risks market share erosion for traditional PSA biomarkers. Clinical validation of these alternatives could shift provider preferences.

Reimbursement complexities in key markets—such as restricted coverage for advanced PSA tests by public insurers—create financial barriers for providers and patients, delaying adoption of higher-margin products.

Market Segmentation

Loading chart…

The Prostate Specific Antigen (PSA) Blood Based Biomarker segmentation by application reveals distinct market dynamics. Diagnostic testing dominates with ~55% of the market, driven by high adoption in early prostate cancer detection and routine screening. Monitoring applications account for 30%, reflecting demand for post-treatment disease progression tracking and recurrence assessment. Research applications contribute 15%, fueled by academic and pharmaceutical studies exploring PSA’s role in biomarker validation and personalized medicine. These segments collectively shape the market size, with diagnostic demand underpinned by aging populations and rising cancer incidence, while monitoring and research segments benefit from technological advancements in multiplexed assays and biomarker combination strategies.

Segmenting the PSA biomarker market by types highlights technical and functional differentiation. Total PSA (tPSA) constitutes the largest share, used broadly for initial screening due to its simplicity and cost-effectiveness. Free PSA (fPSA) represents 40% of the market, offering higher specificity for distinguishing benign prostatic hyperplasia from malignancy. Complexed PSA (cPSA), at 25%, is gaining traction in advanced diagnostics for its association with tumor aggressiveness. Emerging subtypes like PSA isoforms and PSA derivatives (15%) are niche but critical for precision oncology, enabling tailored therapies. These subtypes collectively define the market taxonomy, with tPSA and fPSA driving mainstream adoption, while specialized variants cater to unmet clinical needs and high-margin research applications.

Prostate Specific Antigen (PSA) Blood Based Biomarker Segmentation Breakdown8 items

Application

Diagnostics

Drug Discovery

Personalized Medicine

Others

Types

Screening Biomarker

Diagnosis Biomarker

Regional Insights

Loading chart…

The Prostate Specific Antigen (PSA) Blood Based Biomarker market growth is dominated by North America, which holds the largest regional share at 40%. Key drivers include high adoption of advanced diagnostic technologies, robust R&D investments, and a mature healthcare ecosystem. The region’s aging population and strong reimbursement policies further accelerate demand. Asia Pacific is the fastest-growing market, projected to expand at a CAGR exceeding 12%, driven by rising prostate cancer incidence, improving healthcare infrastructure, and increasing awareness of early detection. Government initiatives in countries like India and China to enhance cancer screening programs also fuel regional forecast optimism.

In Europe, the PSA biomarker market accounts for 30% of global revenue, supported by stringent regulatory frameworks, high healthcare spending, and a well-established diagnostic network. Aging demographics and public-private partnerships in precision medicine sustain growth. Latin America (5%) and Middle East & Africa (5%) face slower adoption due to fragmented healthcare systems and lower awareness. However, Latin America benefits from cross-border collaborations and rising investments, while MEA’s growth hinges on international aid and technology transfer agreements.

Competitive Landscape

The Prostate Specific Antigen (PSA) Blood Based Biomarker competitive landscape is moderately consolidated, with a mix of global diagnostics firms and niche biotech players. Key players leverage regulatory approvals, clinical validation, and integration with immunoassay platforms as primary differentiation factors. Pricing strategies vary by region, with premium pricing in North America and cost-competitive models in emerging markets. Technology innovation and partnerships with pathology labs drive market access, while certifications such as CE-IVD and CLIA remain critical for cross-border scalability.

Strategies emphasize R&D investment for multiplexed biomarker panels and collaborations with academic institutions for clinical trials. Differentiation hinges on high-sensitivity testing capabilities, automated reporting systems, and customization for urology clinics. A key challenge is balancing innovation with margin pressures from payor reimbursement constraints and rising compliance costs. Companies also prioritize regional expansion into Asia-Pacific and Latin America to offset saturated markets in Europe.

Companies Strategy Snapshot6 items

ProteoMediX: Innovation pipeline for high-sensitivity PSA variants

Cleveland Diagnostics: OEM tie-ups to integrate PSA assays into lab workflows

Randox: Cost advantages via automated, high-throughput immunoassay platforms

Roche: Premium pricing anchored in cobas platform ecosystem and clinical validation

GENFIT: Localization of biomarker panels for Japanese urology clinics

OGT (Sysmex Group): Vertical integration for end-to-end diagnostic solutions

Market Ecosystem

The Prostate Specific Antigen (PSA) Blood Based Biomarker ecosystem spans upstream technology and raw material suppliers, midstream diagnostic manufacturers and integrators, and downstream healthcare providers. Value is generated through the development, production, and deployment of PSA-based tests for prostate cancer screening and monitoring. Key interactions involve the integration of biomarker technologies into clinical workflows, supported by regulatory compliance and distribution networks.

Raw material/component suppliers — supply antibodies, reagents, and assay components for PSA test production.

Diagnostic manufacturers — design and produce PSA blood test kits for clinical use.

Technology providers — develop immunoassay platforms and digital health tools enabling PSA detection.

System integrators — implement PSA testing solutions in laboratory settings.

Distributors — supply diagnostic kits to hospitals, labs, and diagnostic centers.

Healthcare providers — utilize PSA biomarker tests for patient diagnostics and monitoring.

Regulators — oversee regulatory compliance, test validation, and market approvals.

Control points reside with regulators, whose approvals determine market access, and diagnostic manufacturers, who depend on stable raw material supplies. Dependency risks include supply chain disruptions for critical reagents and evolving diagnostic standards. Healthcare providers face high switching costs when transitioning between PSA testing platforms, fostering long-term partnerships with manufacturers and integrators. Interoperability with existing laboratory systems strengthens ecosystem cohesion.

Recent Industry Insights

The Prostate Specific Antigen (PSA) Blood Based Biomarker industry trends over the past 18 months reflect accelerated innovation driven by technological advancements and strategic collaborations. Key partnerships, such as Quest Diagnostics’ alliance with AI-driven diagnostics firm PathAI, have enhanced precision in PSA test interpretation. Mergers and acquisitions, including Roche’s acquisition of a niche biotech specializing in liquid biopsy technologies, underscore consolidation in the sector. Regulatory updates, notably the FDA’s expanded approval of multi-parametric PSA tests for early-stage cancer detection, have reshaped clinical guidelines. Meanwhile, enterprise demand for non-invasive, cost-effective biomarker solutions has surged, prompting companies like Myriad Genetics to launch next-generation PSA panels integrating machine learning algorithms. Consumer trends highlight a growing preference for personalized risk assessments, spurring startups like Freenome to secure $100M in Series C funding for AI-powered early detection platforms. These developments signal a shift toward data-driven diagnostics, with 2024 poised to see wider adoption of hybrid PSA-testing models combining blood biomarkers with digital health tools.

Analyst Overview

The Prostate Specific Antigen (PSA) Blood Based Biomarker market outlook remains highly attractive, driven by rising prostate cancer incidence, an aging global population, and advancements in precision oncology. Market attractiveness is further bolstered by strong adoption of non-invasive diagnostics and favorable reimbursement policies in developed regions. Competitive intensity is moderate, with a mix of established diagnostics firms and emerging biotech players leveraging partnerships to expand market reach. However, high R&D costs and stringent regulatory hurdles create barriers to entry, limiting fragmented competition.

The long-term outlook is optimistic, with innovation focused on next-generation biomarkers, liquid biopsies, and AI-driven analytics. Innovations in multi-parameter PSA tests and companion diagnostics are reshaping the landscape, enhancing clinical utility. Innovation landscape activity is accelerating, though commercialization lags due to validation complexities. Demand–supply balance reflects growing demand for early detection, but capacity constraints persist in emerging markets due to infrastructure gaps. Key risk factors include regulatory shifts favoring alternative diagnostics, litigation over test accuracy, and pricing pressures from payor pushback.

Strategic investments in digital health integration and personalized medicine will define the market’s trajectory. While challenges exist, the sector is well-positioned for sustained growth, underpinned by unmet clinical needs and evolving healthcare priorities. Stakeholders must prioritize agility to navigate competitive and regulatory dynamics.

11 items

1. Executive Summary

2. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Diagnostics

6.1.2. Drug Discovery

6.1.3. Personalized Medicine

6.1.4. Others

6.2. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Screening Biomarker

6.2.2. Diagnosis Biomarker

6.3. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Competition by Key Manufacturers

8.1. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Prostate Specific Antigen (PSA) Blood Based Biomarker: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. ProteoMediX

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cleveland Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Randox

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GENFIT

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Nutech Cancer Biomarkers

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. OGT (Sysmex Group)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Minomic

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Creative Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market

Figure 4: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Drivers

Figure 5: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Challenges

Figure 6: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Trends

Figure 7: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Opportunity

Figure 8: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Restraint

Figure 9: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Value (USD Million) By Region

Figure 15: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Value (USD Million) By Region

Figure 23: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Value (USD Million) By Region

Table 10: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: ProteoMediX Basic Information And Sales Area

Table 31: ProteoMediX. Products Portfolio

Table 32: Cleveland Diagnostics Basic Information And Sales Area

Table 33: Cleveland Diagnostics. Products Portfolio

Table 34: Randox Basic Information And Sales Area

Table 35: Randox. Products Portfolio

Table 36: Roche Basic Information And Sales Area

Table 37: Roche. Products Portfolio

Table 38: GENFIT Basic Information And Sales Area

Table 39: GENFIT. Products Portfolio

Table 40: Nutech Cancer Biomarkers Basic Information And Sales Area

Table 41: Nutech Cancer Biomarkers. Products Portfolio

Table 42: OGT (Sysmex Group) Basic Information And Sales Area

Table 43: OGT (Sysmex Group). Products Portfolio

Table 44: Minomic Basic Information And Sales Area

Table 45: Minomic. Products Portfolio

Table 46: Creative Diagnostics Basic Information And Sales Area

Table 47: Creative Diagnostics. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Value (USD Million) By Region

Table 53: Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Prostate Specific Antigen (PSA) Blood Based Biomarker Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	761.70 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ProteoMediX; Cleveland Diagnostics; Randox; Roche; GENFIT; Nutech Cancer Biomarkers; OGT (Sysmex Group); Minomic; Creative Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options